Uvesterol Vitamine ADEC oral solution is applied across therapeutic domains where additional symptomatic support is needed due to nutritional shortfalls. Its core use is in conditions presenting with acute or disruptive episodes linked to deficiency, such as those manifesting as symptoms related to systemic imbalance, physical discomfort, or physiological strain. The medicine is applied in clinical settings that involve acute or unstable symptom patterns.

This combination product contributes to improved comfort during periods of heightened symptoms by assisting with maintaining functional stability. The range of conditions where it is relevant includes those involving episodic manifestations, fluctuating symptoms, and inflammatory or irritative states tied to micronutrient deficiency. In these situations, the medicine provides supportive relief when symptoms interfere with routine activities. It may assist with maintaining a sense of stability when symptoms are more noticeable. This contributes to easing the overall symptom load and supports patients to cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

---

Regulatory References

1. ANSM's Therapeutic Use Protocol

Population Eligibility and Contraindications

The eligibility profile for Uvesterol A D E C is highly specific, as defined by regulatory authorities, focusing on specific populations at risk of deficiency. The medicine is officially permitted for newborns and infants for the prophylaxis of vitamin deficiency and for patients with confirmed malabsorption syndromes.

Absolute Contraindications

Use of Uvesterol A D E C is strictly prohibited for any individual with the following metabolic or immunological conditions:

• Hypercalcemia (abnormally high blood calcium levels)
• Hypercalciuria (abnormally high urine calcium levels)
• Calcium lithiasis (kidney stones)
• Hypersensitivity or allergy to any of the active ingredients (Vitamins A, D, E, C) or excipients.

Age and Condition Restrictions

While newborns and infants are the primary approved populations, regulatory documents specify limitations for non-standard use. Specific age thresholds and setting limitations apply in malabsorption protocols, restricting use to ambulatory patients from one month or hospitalized patients older than two years under defined conditions. Eligibility status is officially not established for the general adolescent, adult, or geriatric populations, reflecting the product's narrow pediatric focus.

Interactions with other medicines and products

The interaction profile for Uvesterol A D E C is officially structured around managing cumulative exposure risk and additive pharmacodynamic effects, according to regulatory documentation.

Formally Restricted Combinations

Co-administration with systemic retinoids, such as Tretinoin, is formally restricted. This measure is required to prevent an increase in total retinoid exposure from both the interacting medicine and the Retinol (Vitamin A) component, thereby mitigating the labeled risk of hypervitaminosis A.

Pharmacodynamic Interactions and Monitoring

The polyvitaminic preparation's Vitamin D2 (Ergocalciférol) component has an additive effect when combined with calcium supplements or high dietary calcium intake. Due to this pharmacodynamic interaction, regular monitoring of urinary calcium is considered necessary when these substances are co-administered.

Mandatory Administrative Constraints

Official labeling requires accounting for the total intake of Vitamin A and Vitamin D from all sources, including this product and any other supplements or fortified foods like infant formulas, to ensure prevention of overdosage. Additionally, due to a mild stimulating effect attributed to the Vitamin C component, administration is preferably avoided in the late day, as documented in the product information.

The mechanism of action for Uvesterol A D E C is derived from the coordinated pharmacodynamics of its four component vitamins.

Vitamin A (as retinol) acts on target tissues, including epithelial cells, by first being metabolized to its active forms, retinaldehyde and retinoic acid. Retinoic acid is an agonist for the Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs), which are nuclear transcription factors. Upon ligand binding, the RAR-RXR heterodimers translocate to the DNA's Retinoic Acid Response Elements (RAREs), modulating the transcription of genes responsible for cellular differentiation and growth.

Vitamin D (as ergocalciferol, D2) is a prohormone. It undergoes 25-hydroxylation in the liver by CYP2R1 to 25-hydroxyvitamin D2, followed by 1alpha-hydroxylation in the kidney by CYP27B1 to form the active hormone, 1,25-dihydroxyvitamin D2 (calcitriol). Calcitriol acts as an agonist for the Vitamin D Receptor (VDR), a nuclear receptor. The calcitriol-VDR complex heterodimerizes with RXR and binds to Vitamin D Response Elements (VDREs) on the genome. This interaction regulates the transcription of genes, including those encoding calcium and phosphate transport proteins in the intestinal enterocytes, thereby modulating the systemic concentrations of these minerals.

Vitamin E (alpha-tocopherol) functions primarily as a chain-breaking antioxidant within cell membranes. It preferentially localizes to the lipid bilayer, where it reacts with unstable lipid peroxyl radicals, terminating the lipid peroxidation chain reaction and stabilizing the membrane structure.

Vitamin C (ascorbic acid) is a water-soluble reducing agent and cofactor for several metalloenzymes, including those involved in collagen biosynthesis (e.g., prolyl hydroxylase). It maintains the required reduced state of metal ions (e.g., Fe^2+), supporting hydroxylation reactions and contributing to the body's overall redox homeostasis.

How to Use Uvesterol A D E C

Uvesterol A D E C is a polyvitaminic preparation administered solely via the oral route as an aqueous solution. The medicine is officially used for the prophylaxis of deficiency in the newborn and infant population, following a fixed daily schedule. The administration protocol involves strict procedural requirements to ensure accurate dosing and proper intake.

The standard dose volume is 0.3 mL per day, which delivers 3000 IU Vitamin A, 1000 IU Vitamin D2, 5 mg Vitamin E, and 50 mg Vitamin C. The regimen does not include instructions for adult use.

Administration Scope

Feature	Instruction
Route of administration	Oral route only.
Dosing schedule	A single standard dose of 0.3 mL per day.
Timing	Must be given before the daily feeding (breast or bottle). Preferably avoided toward the end of the day.
Preparation	Must be systematically diluted in a small volume (approx. 2 mL) of milk or water.
Age-group use	Indicated for newborns and infants. Dosage may be subject to adaptation based on plasma vitamin levels in specific clinical contexts.
Duration	Use must not be prolonged without guidance from a healthcare professional.

Special Procedural Conditions

The protocol requires the exclusive use of the oral dosing pipette provided to ensure accurate measurement. Administration must take place while the child is awake and positioned semi-seated; the child must not be laid down immediately following the dose. These procedural steps define the standardized use of the medicine.

Uvesterol A D E C: Recent Clinical Evidence

Research on this specific vitamin combination has primarily focused on preterm and very-low-birth-weight (VLBW) infants where vitamin stores are often low at birth and rapidly depleted. The aim of these studies is to assess whether supplementation helps achieve sufficient circulating levels of the fat-soluble vitamins (A, D, E) and water-soluble vitamin (C).

---

Key Findings in Neonatal Populations

• Vitamin D Status: Studies evaluating the use of Uvesterol A D E C in preterm infants, often alongside breast milk or formula feeding, indicate that the supplement contributes to reaching target levels of 25-hydroxyvitamin D (25(OH)D), the marker for Vitamin D status, within the first few months of life. This achievement is critical for bone development and overall health in infants.
• Vitamin A and E: Findings suggest that plasma concentrations of Vitamin A and E generally increase over the study period with supplementation. However, in some cohorts, these levels did not always reach the values considered normal for full-term infants and young children by the end of the study.
• Nutritional Impact: The type of nutrition (breast milk versus formula) did not appear to significantly affect the resulting plasma vitamin concentrations of A, D, or E when supplemented with the product.

---

Safety Considerations from Research

Clinical trials documented the importance of proper administration to avoid adverse events like aspiration or vagal discomfort, which have been linked to the method of delivery, especially when administering the solution via pipette to infants. Separately, research has explored the risk of hyperosmolality when multi-vitamin supplements are added to small volumes of fortified human milk, suggesting dilution may be necessary to maintain safe levels.

Key Studies & References

1. Safety and Efficacy of Multi-Vitamin Supplements in Preterm Infants: A Clinical Trial Assessment

Common questions about Uvesterol A D E C (FAQ)

---

Q: What are the most common non-serious side effects people report after starting Uvesterol A D E C?

According to official product information, the frequency of non-serious side effects like a rash, nausea, or vomiting is typically designated as 'Not Known'. This designation reflects that frequency cannot be estimated from the available data, which relies primarily on post-marketing spontaneous reporting.

---

Q: Is Uvesterol A D E C considered safe for someone with known kidney issues?

Official safety constraints include a caution for individuals with pre-existing conditions that affect their calcium balance, such as Severe Renal Impairment. This is because the Vitamin D component carries a labeled risk of Hypercalcemia (too much calcium in the blood), which can affect kidney health.

---

Q: Are there different formulations or strengths of Uvesterol A D E C available?

The product described in official regulatory documents is specifically an oral solution only. It contains a fixed concentration of the four vitamins, corresponding to a single standard dose volume (0.3 mL) designated for the infant and newborn population.

---

Q: What should be done if a rash appears after starting Uvesterol A D E C?

A rash is described in regulatory texts as a possible, but infrequent, manifestation of an Immune System Disorder (a hypersensitivity reaction or allergic-type response). The presence of such an adverse reaction is a reason to consult with a healthcare professional.

---

Q: Is Uvesterol A D E C gluten-free or suitable for people with dietary restrictions?

Official documents list the active ingredients and certain excipients, such as Propylèneglycol and the artificial sweetener Saccharine sodique. Suitability for specific dietary needs or restrictions requires a review of the full list of ingredients against individual requirements.

---

Q: Is it necessary to shake the bottle before using Uvesterol A D E C drops?

The official administration protocol includes specific procedural requirements, such as dilution with a small volume of water or milk, and the exclusive use of the provided pipette. However, the regulatory instructions do not explicitly include a direction to shake the bottle before use.

---

Q: Does Uvesterol A D E C contain sugar or artificial sweeteners?

Based on official formulation details, the product does not contain sugar, but it does contain the artificial sweetener Saccharine sodique (Sodium Saccharine).

Storage and Disposal Conditions

The storage of Uvesterol A D E C oral solution is strictly defined by regulatory requirements to ensure the product maintains its labeled stability, protecting the polyvitaminic content.

Storage/Disposal Requirement	Official Labeled Condition
Temperature	Must be stored at a temperature not exceeding 25 °C
Protection	Must be conserved protected from light (A l'abri de la lumière)
Shelf-Life	Total shelf-life before opening is 18 months, when stored correctly
Child Safety	Must be kept out of the sight and reach of children
Handling	The dosing pipette must be rinsed with water after each use
Disposal	Unused or expired solution must be managed by returning to a pharmacy (take-back programs)

These constraints establish the required environment for the solution, which must be protected from higher temperatures and light sources. The labeled instructions for disposal ensure that unused product follows standard pharmaceutical waste procedures.